Feeds:
Posts
Comments

Archive for the ‘BMS’ Category

*****

Impactiviti Daily will not be published next week, as I will be attending the annual Society of Pharmaceutical and Biotech Trainers conference (SPBT) in Orlando.

TODAY’S NEWS:

As the pre-ASCO news heats up, the big headline will be leukemia treatments – specifically, BMS‘ Sprycel and Novartis‘ Gleevec and Tasigna (just inTasigna shown superior to Gleevec in slowing CML: 18-month results). Treatments in this class, by the way, are something near miracle drugs. They’ve totally revolutionized blood cancer treatments. In related news, Novartis’ Afinitor (approved for kidney cancer) meets goals in a trial for pancreatic cancer.

Why should you be interested in a “nanosponge”? Well, there’s this – Scientists have found that a delivery system based on a technique called nanosponge is three to five times more effective at reducing tumor growth than direct injectionmore

Will Amgen‘s new osteoporosis drug Prolia find its true home in oncology treatment? – The company has also applied for FDA approval to market the drug to breast cancer and prostate cancer patients who are undergoing a hormone treatment that weakens their bones. What’s more, the company is conducting tests designed to show that Prolia prevents cancer from spreading to the bones — an indication that could push sales of the drug to as much as $6 billion annually, some analysts predictmore Also – huge sales force push for Prolia.

20% of high school students abuse prescription drugs. Wow – sobering.

RECOMMENDED

Simulations/Gaming. Live training simulations, digital sims (eLearning) and on-line games – our partner network has the expertise you need.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

How to reduce e-mail ping-pong. You know all that back-and-forth? Here’s a way to undercut it at the start!

JUST FOR FUN

See-through animals. Ten of them. Amazing.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

TriCor = placebo? Not good news for Abbott A popular triglyceride-lowering drug that has been taken by millions of Americans failed to prevent heart disease in a big federal study being presented todaymore

FDA to Eli Lilly/Amylin on once-weekly Byetta: No.

OSI to Astellas: No.

FDA to Plavix (from BMS and Sanofi): black-box warning.

RECOMMENDED

Negotiations Training/Presentation Training – Your sales people, account managers, leaders and executives need  to grow in these skills. We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

You’ve heard all about reach and frequency. How about each and recently? And, when it comes to Pharma and Social Media: One or Many?

JUST FOR FUN

Dogs filmed at 1,000 frames per second. You’ve never seen dogs jump quite like this before.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

*****

TODAY’S NEWS

New blood thinner looking good; superior to Lovenox? – Bristol-Myers Squibb Co.’s and Pfizer Inc.’s experimental blood thinner prevented dangerous blood clots from forming after knee replacement surgery better than Sanofi-Aventis’s Lovenox in a European study. The company-funded trial, dubbed Advance-2, found patients given apixaban pills twice daily were 38 percent less likely to develop clots deep in the legs, in the lungs or die within two weeks than those given intravenous Lovenox starting before the operation. People in both groups had a similar risk of bleeding, a feared complication of blood-thinning medications. SA..more BMS is talking about 60 drugs in testing phase these days…

Eisai‘s sales to go down by more than half – Japan’s No.4 drugmaker, said it expects annual U.S. sales of its flagship Alzheimer’s drug Aricept to fall 60 percent in three years, hit by the expiration of the drug’s patent later this yearmore

The 10 scariest pharma and healthcare YouTube videos. From Dose of Digital blog.

Need new sales reps? Poach.

RECOMMENDED

Social Media Strategy/Execution – If you’re looking to employ social media in pharma communications/marketing, a thousand providers will tell you they can help. But who is really the best for your needs?. We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Tearing up the rule book on pharma sales force compensation (from Pharmaceutical Executive). And survey says: the glory days aren’t coming back.

JUST FOR FUN

What are “crepuscular rays”? You’ll recognize them when you see them! 20 gorgeous examples.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

NEXT WEEK: IIRUSA’s ePharma Summit, Philadelphia, PA. I’ll be there, reporting live via social media. You?

TODAY’S NEWS

AstraZeneca looking down the barrel of 26,000 Seroquel lawsuits. Or so.

New treatment for debilitating hand condition – The Food and Drug Administration Tuesday approved the first drug designed to treat a debilitating hand condition known as Dupuytren’s contracture. The drug, called Xiaflex, is manufactured by Auxilium Pharmaceuticals Inc. of Malvern, Penn., and the company expects to begin selling it by the end of March. An FDA advisory panel in September unanimously recommended approval of the drug…more

A new kind of drug export – BMS employee accused of stealing secrets to try to start own pharma company in India!

Six key areas of learning for pharma and healthcare marketing in 2010.

RECOMMENDED

Outsourcing – Considering outsourcing training technology functions, or meetings/logistics, or even the entire training department? Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations of outsource partners.

PLUS

Want to know the latest about Facebook adoption, and how it impacts business? Read this great post by Jay Baer. And, while we’re talking social networking: what is the goal as it relates to business (my post yesterday on Holistic Common Sense). Plus, Jon Richman on the Seven (soon to be Nine) Uses of Social Media in Business. And, over 1/2 of all adults now go online for health information, while physicians are very heavy users of internet resources (did you know that 1/3 have changed a patient treatment based on an internet search?)

JUST FOR FUN

When engineers get laid off and have too much time on their hands. Sheesh!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Whew! The back-to-back conference marathon is now over, and we can get back to our regular pharma news reporting. Here’s what’s up today…

TODAY’S NEWS

Everyone’s talking about the Zetia/Niaspan study – its results, its significance, its limitations. Bottom line – I can’t see how this can be good for Merck. More here. And Jim Edwards analyzes the damage control spin effort here.

Always a headline topic: female sexual desire treatments. The more you read about this drug (experimental ‘flibanserin’ from Boehringer-Ingelheim), however, the more you wonder if the purported effect will be worth the expense and the side effects.

BMS pushing Mead-Johnson out of the nest. It is amazing to me how drug companies cycle through periods where they diversify, then spin divisions off…

Novartis: half a dose of H1N1 vaccine may be enough. Now that’s how to increase vaccine supply!

If you’re going to blow the whistle, I guess it’s important to get on to the field of play! Whistleblower lawsuit against J&J dismissed.

RECOMMENDED

Leadership – talent selection. How is your organization choosing leaders? Impactiviti’s provider network has proven, best-in-class talent selection/management solutions. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Is this drug a frog, or a prince? I dunno, but I like the picture…!

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Note: Impactiviti Daily is going to be published somewhat irregularly over the next 4 weeks, as we’re in the heart of “conference” season and I’m attending/speaking at several events over the next month. We’ll do our best to keep you updated!

TODAY’S NEWS

Pharma sales reps should be paid overtime? This is getting interesting – Novartis sales reps fighting for overtime pay just got a powerful ally. The US Department of Labor filed an amicus brief with a federal appeals court contending that a lower court was wrong to toss their lawsuitmore

AstraZeneca: KY says pony up $14.7M for marketing the spread – The ruling is the latest legal setback for AstraZeneca over the way its pricing. The drug maker was ordered by a jury in Alabama last year to pay $215 million for overcharging that state’s Medicaid program (back story). A judge later reduced that to $160 million, and AstraZeneca is appealing. In 2007, a federal judge in Boston ordered the drug maker to pay $12.9 million for overcharges, and an appeals court last month upheld the decisionmore

BMS cuts 25% of Abilify sales force: any insiders have the actual number? – Bristol-Myers Squibb Co. cut the sales force for its second best-selling drug, the antipsychotic Abilify, six months after extending its contract to market the product with Tokyo-based Otsuka Pharmaceutical Co. About 25 percent of the positions were eliminated, Brian Henry, a spokesman for New York-based Bristol-Myers, said yesterday in a telephone interview. The move happened this week, he said. He declined to give the number of jobs cut…more

Pfizer completes acquisition of Wyeth; cuts/closings coming; also slips updated logo into the mix!

RECOMMENDED

Managed Care/Account Manager training. Impactiviti’s partner network has a broad range of offerings for managed care training, from off-the-shelf to custom workshops, and more. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for brainstorming and recommendations.

PLUS

Time. Talent. And Magic. Be sure to “set your own table” as you develop your career. From the StickyFigure blog.

JUST FOR FUN

Coming up this month:

Oct. 26-27 – Kru Research’s e-Patient Connections conference, Philadelphia, PA. I’ll be speaking and live-blogging. Here’s a discount code to save $500 off your registration: SW500

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Now Available – My archived interview on Social Media in Pharma with Paul Chaney – feel free to forward the link (http://bit.ly/29kAoN) to your colleagues.

TODAY’S NEWS

BMS/Astra diabetes drug cleared in Europe ONGLYZA is indicated as a once-daily 5 mg oral tablet dose in adult patients with type 2 diabetes mellitus to improve glycaemic controlmore

FDA panel gives thumbs up to new GSK cancer drug –  A Food and Drug Administration panel Monday unanimously backed a proposed GlaxoSmithKline PLC drug for treating kidney cancer, despite agency concerns about a risk of severe liver injury. Glaxo is seeking FDA approval of the drug, pazopanib, to treat patients with advanced kidney cancer. The product was reviewed by outside medical experts who serve on the agency’s oncologic drugs advisory committeemore

Novartis CEO Vasella comes out swinging against animal rights terrorists. Good for him.

Physician smartphone usage – on the rise!

RECOMMENDED

Virtual Worlds and other on-line platforms for training or meetings. Impactiviti’s suite of partners can help you design and roll-out these advanced applications. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) to talk.

PLUS

Eighteen minutes that will rattle your world and challenge your assumptions about motivation in business. Dan Pink at TED – a great presenter, and very thought-provoking.

JUST FOR FUN

Dilbert on management evaluation.

Coming up this month:

DigitalPharma

Oct. 19-21 – eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Older Posts »